TW200507875A - Remedy for diabetes - Google Patents

Remedy for diabetes

Info

Publication number
TW200507875A
TW200507875A TW093110794A TW93110794A TW200507875A TW 200507875 A TW200507875 A TW 200507875A TW 093110794 A TW093110794 A TW 093110794A TW 93110794 A TW93110794 A TW 93110794A TW 200507875 A TW200507875 A TW 200507875A
Authority
TW
Taiwan
Prior art keywords
stem cell
cell mobilization
factors
treating diabetes
remedy
Prior art date
Application number
TW093110794A
Other languages
English (en)
Inventor
Yoshiki Kawabe
Yuichiro Adachi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200507875A publication Critical patent/TW200507875A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093110794A 2003-04-15 2004-04-15 Remedy for diabetes TW200507875A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003110561 2003-04-15

Publications (1)

Publication Number Publication Date
TW200507875A true TW200507875A (en) 2005-03-01

Family

ID=33295957

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093110794A TW200507875A (en) 2003-04-15 2004-04-15 Remedy for diabetes

Country Status (9)

Country Link
US (1) US7662366B2 (zh)
EP (1) EP1629851A1 (zh)
JP (1) JPWO2004091661A1 (zh)
KR (1) KR20050114275A (zh)
CN (1) CN1780642A (zh)
AU (1) AU2004229285A1 (zh)
CA (1) CA2522322A1 (zh)
TW (1) TW200507875A (zh)
WO (1) WO2004091661A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070006668A (ko) * 2003-10-14 2007-01-11 추가이 세이야쿠 가부시키가이샤 신장 질환 치료제
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
KR100908628B1 (ko) * 2008-03-21 2009-07-21 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물
US20120093764A1 (en) * 2010-10-19 2012-04-19 Dipnarine Maharaj Treatment of diabetes using g-csf and hyperbaric oxygen
WO2012159044A1 (en) * 2011-05-18 2012-11-22 Wellstat Therapeutics Corporation Stem cell mobilization and tissue repair and regeneration
WO2014031745A2 (en) * 2012-08-21 2014-02-27 Nayer Ali Materials and methods for modulating glucose uptake
US9428552B2 (en) 2012-11-19 2016-08-30 Wellstat Therapeutics Corporation Stem cell mobilization and tissue repair and regeneration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US6001647A (en) * 1994-04-28 1999-12-14 Ixion Biotechnology, Inc. In vitro growth of functional islets of Langerhans and in vivo uses thereof
CN1202112A (zh) * 1995-11-09 1998-12-16 武田药品工业株式会社 增强胰腺功能的组合物
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US6610535B1 (en) * 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
JP2001233784A (ja) * 2000-02-23 2001-08-28 Morinaga Milk Ind Co Ltd インターロイキン−１８産生促進剤
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
GB0031390D0 (en) * 2000-12-21 2001-02-07 Imp College Innovations Ltd Methods
US20040136969A1 (en) * 2002-10-02 2004-07-15 New York University Adult bone marrow derived stem cells

Also Published As

Publication number Publication date
AU2004229285A1 (en) 2004-10-28
WO2004091661A1 (ja) 2004-10-28
JPWO2004091661A1 (ja) 2006-07-06
US20070098680A1 (en) 2007-05-03
CA2522322A1 (en) 2004-10-28
CN1780642A (zh) 2006-05-31
KR20050114275A (ko) 2005-12-05
EP1629851A1 (en) 2006-03-01
US7662366B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
WO2006074308A3 (en) Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
WO2006031931A3 (en) Reducing er stress in the treatment of obesity and diabetes
ES2169128T3 (es) Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos.
AR090143A2 (es) Composicion farmaceutica para inhibir el crecimiento de celulas anormales
HUP0401590A2 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
WO2009023566A3 (en) Method of treating autoimmune disease with mesenchymal stem cells
TW283645B (zh)
UA91521C2 (ru) Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
RS49981B (sr) Upotreba derivata hidroksilamina za dobijanje farmaceutskih kompozicija korisnih za povećanje ekspresije i aktivnosti molekulskih šaperona
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
PL1885382T3 (pl) Sposoby stosowania komórek pochodzących z tkanki tłuszczowej w leczeniu stanów układu sercowo-naczyniowego
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
TW200507875A (en) Remedy for diabetes
Malamed Buffering local anesthetics in dentistry
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
TR199903142T2 (xx) Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi.
MY158929A (en) Pharmaceutical combination
WO2005089426A3 (en) Method of treating sepsis
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
PL1660115T3 (pl) Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi
WO2008143123A1 (ja) 病原性微生物の殺滅方法
DK1509523T3 (da) Triazaspiro-forbindelser anvendelige for at behandle eller forhindre smerte